SEC Tracker
Get the app
CELZ · XBRL financial data

Creative Medical Technology Holdings financial statements, every quarter

The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

Download Excel Download CSV
How these numbers work
  • Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
  • Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
  • * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
  • 0 means a filing states zero; a dash (—) means no filing states that number.
  • “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
  • Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
  • Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
  • Shares outstanding come from each filing's cover page, as of the date printed there.
  • Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

CSV

Fiscal quarters (CELZ's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Revenue63*0803*3003*00
Cost of revenue21*0301*1001*00
Gross profit42*0502*2002*00
Research and development993349*422925582472*743501465550*542459
Selling, general and administrative5311,399*6716764991,393*8887327771,367*8891,080
Total operating expenses1,5471,774*1,1231,6301,1101,888*1,6621,2641,2731,948*1,4591,562
Operating income (loss)(1,543)(1,772)*(1,123)(1,625)(1,110)(1,886)*(1,660)(1,264)(1,273)(1,946)*(1,459)(1,562)
Interest expense——0—————————
Income tax expense (benefit)00*0000*0000*00
Net income (loss)(1,454)(1,679)*(1,042)(1,558)(1,040)(1,854)*(1,638)(1,233)(1,236)(1,888)*(1,405)(1,512)
Earnings per share, diluted USD per share——0.73(1.11)(0.75)—0.83(0.48)(0.48)—(0.38)(0.41)
Weighted average shares, diluted thousands of shares——1,4211,4051,3921,701*1,9812,5812,5812,383*3,7023,702

Balance sheet

CSV

Fiscal quarters (CELZ's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Cash and cash equivalents4,5073,4679,0077,4716,2605,9407,7036,5445,3767,2085,7238,714
Inventory8773321110125125
Prepaid and other current assets6127719112968193140883513910570
Total current assets12,04410,2719,2057,6046,3316,1357,8446,6335,4127,3996,0599,019
Total assets12,51410,7159,6207,9906,8886,6698,3477,1055,8537,8106,4419,378
Accounts payable367317337322274274272263247271293684
Accrued liabilities4040404043400000——
Total current liabilities421371391376331328286278261285308699
Total liabilities421371391376331328286278261285308699
Accumulated deficit(57,420)(59,098)(60,140)(61,698)(62,738)(64,592)(66,230)(67,463)(68,699)(70,587)(71,992)(73,504)
Total stockholders' equity12,09210,3449,2297,6136,5576,3418,0616,8285,5927,5156,1108,655
Total liabilities and equity12,51410,7159,6207,9906,8886,6698,3477,1055,8537,8106,4419,378
Common shares outstanding (cover page) thousands of shares1,3821,3571,3481,3381,7481,7482,5862,5812,5813,6973,6976,593

Cash flows

CSV

Fiscal quarters (CELZ's year ends in late December)

In thousands of dollarsSep 30, 2023Dec 31, 2023Mar 31, 2024Jun 30, 2024Sep 30, 2024Dec 31, 2024Mar 31, 2025Jun 30, 2025Sep 30, 2025Dec 31, 2025Mar 31, 2026Jun 30, 2026
Net income (loss)(1,454)(1,679)*(1,042)(1,558)(1,040)(1,854)*(1,638)(1,233)(1,236)(1,888)*(1,405)(1,512)
Stock-based compensation99*9999*30*0*0*00*
Net cash from operating activities(1,305)*(1,895)*(897)(1,469)*(986)*(1,950)*(1,592)(1,159)*(1,169)*(1,938)*(1,323)(1,472)*
Net cash from investing activities1,822*1,126*6,5200*(200)*0*00*0*(51)*(175)0*
Proceeds from issuing common stock—year only———year only3,3640*—year only04,465*
Share repurchases192*79*8367*25*0*100*0*0*00*
Net cash from financing activities0*(271)*(83)(67)*(25)*1,630*3,3540*0*3,821*134,463*
Net change in cash—————year only1,762(1,159)*—year only(1,485)2,991*

Compare with peers

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen
  • SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
  • Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
  • Runway shows only for companies burning cash with under $10B of public float.
  • * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
  • A cell reading “not reported” means the filings give no figure for that quarter alone.
CompanyCash ($K)Revenue, quarter ($K)Operating cash flow, quarter ($K)Shares outstandingRunwayQuarter
Creative Medical Technology Holdings8,7140(1,472)*6.6M5.9 quarters 10-QJun 30, 2026
Target Group141,381(223)*617.0M0.1 quarters 10-QJun 30, 2026
Aspira Women's Health47717(2,010)*46.6M0.2 quarters 10-QJun 30, 2026
Soligenix9,811not reported(1,707)*21.8M5.7 quarters 10-QJun 30, 2026
Matinas BioPharma Holdings761not reported(1,836)*14.7M0.4 quarters 10-QJun 30, 2026
Synlogic13,1830(922)*12.2M14.3 quarters 10-QJun 30, 2026
Viskase Holdings7,74795,279454*14.3M— 10-QSep 30, 2026
China Pharma Holdings305948(33)*43.0M9.3 quarters 10-QJun 30, 2026
Xenetic Biosciences6,472661(875)*2.3M7.4 quarters 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.